These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20605906)

  • 1. Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.
    Jones AW; Durante W; Korthuis RJ
    J Pharmacol Exp Ther; 2010 Oct; 335(1):85-91. PubMed ID: 20605906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
    Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
    J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
    Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
    Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
    Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
    Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
    Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
    Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
    Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
    Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats.
    Priviero FB; Zemse SM; Teixeira CE; Webb RC
    Am J Hypertens; 2009 May; 22(5):493-9. PubMed ID: 19247264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation.
    Nimmegeers S; Sips P; Buys E; Brouckaert P; Van de Voorde J
    Cardiovasc Res; 2007 Oct; 76(1):149-59. PubMed ID: 17610859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
    Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
    BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
    Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
    Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
    Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
    Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.
    Feelisch M; Kotsonis P; Siebe J; Clement B; Schmidt HH
    Mol Pharmacol; 1999 Aug; 56(2):243-53. PubMed ID: 10419542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
    Bawankule DU; Sathishkumar K; Sardar KK; Chanda D; Krishna AV; Prakash VR; Mishra SK
    J Pharmacol Exp Ther; 2005 Jul; 314(1):207-13. PubMed ID: 15792996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
    Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
    Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1093-102. PubMed ID: 17596536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
    Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
    Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase.
    Schmidt P; Schramm M; Schröder H; Stasch JP
    Eur J Pharmacol; 2003 May; 468(3):167-74. PubMed ID: 12754054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-fat diet-induced obesity leads to increased NO sensitivity of rat coronary arterioles: role of soluble guanylate cyclase activation.
    Jebelovszki E; Kiraly C; Erdei N; Feher A; Pasztor ET; Rutkai I; Forster T; Edes I; Koller A; Bagi Z
    Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2558-64. PubMed ID: 18408126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
    Chester M; Seedorf G; Tourneux P; Gien J; Tseng N; Grover T; Wright J; Stasch JP; Abman SH
    Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L755-64. PubMed ID: 21856817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.